Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics Inc (NY: LCTX )

0.9062 -0.0366 (-3.88%)
Streaming Delayed Price Updated: 12:46 PM EDT, Sep 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lineage Cell Therapeutics Inc

< Previous 1 2 3 4 Next >
Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage to Present at 2024 BIO International Convention
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Changes to Board of Directors
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering
From Lineage Cell Therapeutics, Inc.
Via Business Wire
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
From Lineage Cell Therapeutics, Inc.
Via Business Wire
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023
From Lineage Cell Therapeutics, Inc.
Via Business Wire
RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury
From Lineage Cell Therapeutics, Inc.
Via Business Wire
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023
From Lineage Cell Therapeutics, Inc.
Via Business Wire
RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
From Lineage Cell Therapeutics, Inc.
Via Business Wire
RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress
From Lineage Cell Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.